Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Science Advances
|
April 5, 2023
ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancer
Dan Li, Yu Zhan, Naitao Wang, et al.
Biorxiv : the Preprint Server for Biology
|
June 19, 2024
TAD hierarchy restricts poised LTR activation and loss of TAD hierarchy promotes LTR co-option in cancer
Elissa W P Wong, Merve Sahin, Rui Yang, et al.
The Journal of Clinical Investigation
|
July 19, 2022
Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses
Juan Yan, Yuedan Chen, Amish J Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 3, 2022
Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors
Ping Chi, Li-Xuan Qin, Niedzica Camacho, et al.
Nature Genetics
|
June 30, 2025
Disruption of TAD hierarchy promotes LTR co-option in cancer
Elissa W P Wong, Merve Sahin, Rui Yang, et al.
Cancer Discovery
|
July 5, 2022
PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry
Amish J Patel, Sarah Warda, Jesper L V Maag, et al.
Nature Genetics
|
January 13, 2025
Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A-menin to bivalent promoters
Naitao Wang, Mohini R Pachai, Dan Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2022
Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor
Ping Chi, Li-Xuan Qin, Bastien Nguyen, et al.
Science (New York, N.Y.)
|
May 26, 2022
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets
Fanying Tang, Duo Xu, Shangqian Wang, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Science Advances
|
April 5, 2023
ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancer
Dan Li, Yu Zhan, Naitao Wang, et al.
Biorxiv : the Preprint Server for Biology
|
June 19, 2024
TAD hierarchy restricts poised LTR activation and loss of TAD hierarchy promotes LTR co-option in cancer
Elissa W P Wong, Merve Sahin, Rui Yang, et al.
The Journal of Clinical Investigation
|
July 19, 2022
Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses
Juan Yan, Yuedan Chen, Amish J Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 3, 2022
Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors
Ping Chi, Li-Xuan Qin, Niedzica Camacho, et al.
Nature Genetics
|
June 30, 2025
Disruption of TAD hierarchy promotes LTR co-option in cancer
Elissa W P Wong, Merve Sahin, Rui Yang, et al.
Cancer Discovery
|
July 5, 2022
PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry
Amish J Patel, Sarah Warda, Jesper L V Maag, et al.
Nature Genetics
|
January 13, 2025
Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A-menin to bivalent promoters
Naitao Wang, Mohini R Pachai, Dan Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2022
Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor
Ping Chi, Li-Xuan Qin, Bastien Nguyen, et al.
Science (New York, N.Y.)
|
May 26, 2022
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets
Fanying Tang, Duo Xu, Shangqian Wang, et al.
Page
of 2